These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38154193)

  • 1. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
    Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
    Maggioni G; Della Porta MG
    Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The International Consensus Classification of myelodysplastic syndromes and related entities.
    Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
    Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
    Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
    Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
    Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of the 5
    Lee C; Kim HN; Kwon JA; Yoon SY; Jeon MJ; Yu ES; Kim DS; Choi CW; Yoon J
    Ann Lab Med; 2023 Sep; 43(5):503-507. PubMed ID: 37080752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
    Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
    Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of WHO-5 and ICC classifications in a series of myeloid neoplasms, considerations for hematopathologists and molecular pathologists.
    Moore ME; Williams E; Pelkey L; Courville EL
    Cancer Genet; 2024 Aug; 286-287():25-28. PubMed ID: 38964162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.
    Bruehl FK; Osman MM; Chen D; Dalland JC
    J Hematop; 2023 Jun; 16(2):65-71. PubMed ID: 38175439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the International Consensus Classification of myelodysplastic syndromes.
    Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
    Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
    Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
    Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
    Hoff FW; Madanat YF
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
    Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
    NEJM Evid; 2022 Jul; 1(7):EVIDoa2200008. PubMed ID: 38319256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
    van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
    Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratifying MDS in the time of precision medicine.
    Cazzola M
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):375-381. PubMed ID: 36485160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
    Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.